Identification of Potent Reverse Indazole Inhibitors for HPK1

Hematopoietic progenitor kinase (HPK1), a negative regulator of TCR-mediated T-cell activation, has been recognized as a novel antitumor immunotherapy target. Structural optimization of kinase inhibitor 4 through a systematic two-dimensional diversity screen of pyrazolopyridines led to the identific...

Full description

Saved in:
Bibliographic Details
Published in:ACS medicinal chemistry letters 2021-03, Vol.12 (3), p.459-466
Main Authors: Yu, Elsie C, Methot, Joey L, Fradera, Xavier, Lesburg, Charles A, Lacey, Brian M, Siliphaivanh, Phieng, Liu, Ping, Smith, Dustin M, Xu, Zangwei, Piesvaux, Jennifer A, Kawamura, Shuhei, Xu, Haiyan, Miller, J. Richard, Bittinger, Mark, Pasternak, Alexander
Format: Article
Language:English
Subjects:
Letter
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hematopoietic progenitor kinase (HPK1), a negative regulator of TCR-mediated T-cell activation, has been recognized as a novel antitumor immunotherapy target. Structural optimization of kinase inhibitor 4 through a systematic two-dimensional diversity screen of pyrazolopyridines led to the identification of potent and selective compounds. Crystallographic studies with HPK1 revealed a favorable water-mediated interaction with Asp155 and a salt bridge to Asp101 with optimized heterocyclic solvent fronts that were critical for enhanced potency and selectivity. Computational studies of model systems revealed differences in torsional profiles that allowed for these beneficial protein–ligand interactions. Further optimization of molecular properties led to identification of potent and selective reverse indazole inhibitor 36 that inhibited phosphorylation of adaptor protein SLP76 in human PBMC and exhibited low clearance with notable bioavailability in in vivo rat studies.
ISSN:1948-5875
1948-5875
DOI:10.1021/acsmedchemlett.0c00672